ZhuZhou QianJin Pharmaceutical (600479.SH): Ferrous Succinate Tablets and Escitalopram Oxalate Tablets Obtain Drug Registration Certificates

ZhuZhou QianJin Pharmaceutical (600479.SH) announced that recently, its subsidiary Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. received the Drug Registration Certificates approved and issued by the National Medical Products Administration for Ferrous Succinate Tablets and Escitalopram Oxalate Tablets (5mg, 10mg, 20mg). It is reported that Ferrous Succinate Tablets were first developed by LABORATOIRE X.O and launched in France in 1997, used for the prevention and treatment of iron deficiency anemia. According to Menet pharmaceutical data, the total sales of Ferrous Succinate Tablets in China's hospital and retail markets in 2025 were 456 million yuan. Escitalopram is the single dextrorotatory optical isomer of the bicyclic hydrogenated phthalide derivative racemic citalopram. Escitalopram Oxalate Tablets are used to treat depression and panic disorder with or without agoraphobia. According to Menet pharmaceutical data, the total sales of Escitalopram Oxalate Tablets in China's hospital and retail markets in 2025 were 2.341 billion yuan.